About Celsense
Celsense is a company based in Pittsburgh (United States) founded in 2005. It operates as a B2B. Celsense has raised $7.11 million across 23 funding rounds from investors including NIH, HHS and SBIR. The company has 2 employees. Celsense operates in a competitive market with competitors including HYCOR BioMedical, Exagen, Kypha, TBG Diagnostics and Lophius Biosciences, among others.
- Headquarter Pittsburgh, United States
- Employees 2
- SectorsHealthcare
- Website celsense.com
- Legal Name Celsense Inc
- Total Equity Funding$7.11M (USD)
in 23 rounds
- Latest Funding Round$224.83K (USD), Grant
Sep 2020
- InvestorsNIH
& 3 more
- Employee Count2
Funding Insights of Celsense
Celsense has successfully raised a total of $7.11M across 23 strategic funding rounds. The most recent funding activity was a Grant round of $224.83 thousand completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.11M
- Total Rounds 23
- Last Round Grant — $224,828
- First Round $625,000
(Aug 2006)
- Investors Count 4
Latest 10 of 23 funding rounds of Celsense with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $224,828 | Grant | – | – | |
| Jul 2018 | $1.88M | Grant | – | – | |
| May 2018 | $125,000 | Debt – Conventional | – | – | – |
| Apr 2017 | $710,000 | Series C | – | – | – |
| Jul 2016 | $353,000 | Debt – Conventional | – | – | – |
| Sep 2014 | $175,000 | Series C | – | – | – |
| Aug 2014 | $267,500 | Series C | – | – | – |
| Jan 2014 | $169,296 | Grant | – | – | |
| Aug 2012 | $379,160 | Grant | – | – | |
| Feb 2012 | $125,000 | Series C | – | – | – |
4 investors in total: 4 institutional.
Investors in Celsense
Celsense has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and SBIR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Support is offered for life sciences startups in Pittsburgh. | 2002 | plsg.com | Pittsburgh, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Federal innovation and scientific achievement services are provided. | 1982 | sbir.gov | Lithia Springs, United States |
Investor details for Celsense
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Celsense
3 dated milestones of Celsense across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Celsense is founded.
- Funding First funding round of $625K.
- Funding Latest funding round, Grant, of $225K.
Competitors of Celsense
Celsense operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HYCOR BioMedical, Exagen, Kypha, TBG Diagnostics and Lophius Biosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| hycorbiomedical.com | 1981 | Garden Grove, United States | $99.57M | – | Developer of diagnostic instruments and reagents for autoimmune diseases and allergies | |
| exagen.com | 2002 | Vista, United States | $110.23M | 204 | Diagnostic and monitoring solutions for autoimmune connective diseases are developed. | |
| kypha.net | 2009 | Saint Louis, United States | $16.76M | – | Diagnostic biomarker tests for inflammation and autoimmune diseases are developed. | |
| tbgbio.com | 1989 | Darra, Australia | – | – | Molecular diagnostics kits, instruments, and software are developed and manufactured. | |
| lophius.com | 2008 | Regensburg, Germany | $23.73M | 28 | T-cell-based diagnostics for infectious and immune diseases are developed. | |
| smarthealthdx.com | 1979 | Irvine, United States | $17.29M | – | Precision diagnostics for vascular, metabolic, and oncological diseases are developed. | |
| sanodx.com | 2013 | Wellesley, United States | – | – | A point-of-care platform for chronic wound diagnostics is offered. | |
| predictimmune.com | 2017 | Cambridge, United Kingdom | $18.32M | 15 | Tools for diagnosing immune-mediated inflammatory diseases are developed. | |
| cellidx.com | 2012 | San Diego, United States | $1.34M | 7 | Immunodiagnostic reagents for immunohistochemistry are manufactured and marketed. | |
| immudex.com | 2009 | Copenhagen, Denmark | $16.35M | 42 | Provider of immune monitoring reagents and services for research and clinical use |
Detailed competitors of Celsense
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Celsense
10 companies that operate in the same segment as Celsense (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Celsense
Celsense was founded in 2005 and raised its 1st funding round 1 year after it was founded.
Celsense is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Celsense is a funded company, having raised a total of $7.11M across 23 funding rounds to date. The company's 1st funding round was a Series C of $125K, raised on Aug 2006.
Celsense has 2 employees.
Celsense develops mri agents for tracking transplanted cells in medical applications, focusing on providing healthcare solutions, advancing biotech innovations, medical imaging, and cell tracking. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.
Celsense's top competitors include Exagen, SmartHealth and HYCOR BioMedical.
Celsense has 4 investors. Key investors include NIH, HHS, SBIR, and Pittsburgh Life Sciences Greenhouse.
Celsense operates through Celsense Inc.